Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia

作者：Yu Liu, Wenbing Liu, Anli Lai, Yihan Mei, Ying Wang, Hui Wei, Qing Rao, Runxia Gu, Yingchang Mi, Min Wang, Jianxiang Wang, Shaowei Qiu · 发表于：Blood Cancer Journal · 年份：2024 · DOI：10.1038/s41408-024-01144-1 · 被引用次数：11 · 研究领域：Acute Myeloid Leukemia Research、Lymphoma Diagnosis and Treatment、Acute Lymphoblastic Leukemia research

The t(8;21)(q22;q22) translocation is a common chromosomal abnormality in acute myeloid leukemia (AML). Although t(8;21) AML has a favorable prognosis, ~40% of the patients will eventually relapse [ 1 , 2 ]. Even with allogeneic hematopoietic stem cell transplantation (allo-HSCT), ~20% of patients still relapse, and further treatment is limited [ 3 ]. Notably, KIT high mutation, particularly the KIT-D816 mutation, as well as FLT3 -ITD high alterations, have been reported to confer poor prognosis in t(8;21) AML patients, although there remains controversy [ 4 , 5 , 6 , 7 ]. Other factors like aberrant immunophenotype, high white blood cell (WBC) counts, and high measurable residual disease (MRD) levels evaluated by multiparameter flow cytometry (MFC) also indicate worse outcomes [ 8 , 9 ]. However, these do not fully illuminate the molecular or clinical variations observed in t(8;21) AML. Therefore, it is crucial to improve current risk stratification and identify those with a high risk of relapse as early as possible for tailored treatment strategies.